

Contacts:

**SBI Biotech Co. Ltd.**

Media: Rina Esashi

Phone number: +81-3-5789-3200

[www.sbibiotech.jp](http://www.sbibiotech.jp)

**SBI BIOTECH INITIATE CLINICAL RESEARCH ON IMMUNO CELL THERAPY  
AT KYOTO UNIVERSITY**

TOKYO, JAPAN, June 29, 2011 — SBI Biotech Co., Ltd, a subsidiary of SBI Holdings, Inc. located in Minato-ku, Tokyo, announced today that they will start clinical research on immuno cell therapy (dendritic cell therapy, DC therapy) in July, 2011 in cancer patients with the approval of Kyoto University Hospital. DC therapy is one of the most advanced cancer treatments and its research and development are being promoted in Japan and overseas.

Baylor Research Institute (BRI, located in Dallas, Texas), a leading research center in DC therapy, entered into a licensing and collaboration agreement with SBI Biotech in 2008 for further development of DC therapy in certain cancer indications. Kyoto University and SBI Biotech have been working together for technology transfer of DC therapy from BRI. We will begin the clinical research in patients with melanoma (melanoma; malignant skin cancer).

SBI Biotech hopes to grow dramatically as a joint bio-venture company that spread over China, Korea, Japan, and U.S., collaborating with top researchers and having strong partnerships with world's leading research institutes, bio-venture companies, and global pharmaceutical companies, in the fields of basic research and drug development.

SBI Group will be more actively and directly involved in fostering bio-venture field, through not only investing in bio-venture companies but also bringing up such companies as SBI Biotech and SBI ALApromo (located in Minato-ku, Tokyo) which is conducting research and development of cosmetics, health foods, and pharmaceutical products using 5-aminolevulinic acid (ALA). SBI Group will keep contributing to further growth of domestic biotechnological market.

**About Immuno cell therapy**

Immuno cell therapy is an advanced cancer treatment using immune cells. Immune cells of patients are activated and/or expanded outside of the body and put them back to the patient in order to fight against abnormal cells such as virus-infected or malignant cells. Immuno cell therapy falls into some categories based on the kind of immune cells used.

**About DC (dendritic cell) therapy**

DC therapy is a kind of Immuno cell therapy in which certain types of patient's own immune cells(dendritic cells) are used after being exposed to antigens outside of the body. Main function of DCs is to present antigens on the surface to other cells of the immune system. After injected back into the patients, dendritic cells migrate to the patient's lymph nodes where they initiate T cell responses. DC therapy has some potential advantages such as fewer side effects, cancer cell-specific toxicity, and long-lasting beneficial effects on the immune system.

**Profile of SBI biotech Co.,Ltd.**

SBI Biotech Co., Ltd, the drug subsidiary company of SBI Holdings, Inc. is conducting its business as the global bioventure company by assembling discovery pipelines from Japan, United States, China and Korea. SBI Biotech (ex-Ginkgo Biomedical Research Institute) was established in 2001 by Ken-ichi Arai, M.D., Ph.D.(current President & CEO of SBI Biotech), a global leader in molecular biology and immunology and the former Dean of the Institute of Medical Science, the University of Tokyo. SBI Biotech advances drug discovery and new therapy by utilizing the global network of SBI researchers, receiving investments from venture capital and by collaborating with pharmaceutical companies and university hospitals. For more information on SBI Biotech, please refer to the company's website at [www.sbibiotech.jp](http://www.sbibiotech.jp).